Analysis of the lncRNA–miRNA–mRNA Network Reveals a Potential Regulatory Mechanism of EGFR-TKI Resistance in NSCLC

Analysis of the lncRNA–miRNA–mRNA Network Reveals a Potential Regulatory Mechanism of EGFR-TKI Resistance in NSCLC

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used for patients with EGFR-mutated lung cancer. Despite its initial therapeutic efficacy, most patients eventually develop drug resistance, which leads to a poor prognosis in lung cancer patients. Previous investigat...

Full description

Bibliographic Details
Main Authors:	Dandan Ding, Jufeng Zhang, Zhiming Luo, Huazhen Wu, Zexiao Lin, Weicheng Liang, Xingyang Xue
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Genetics
Subjects:	EGFR-TKIs drug resistance long non-coding RNA LINC01128 lung cancer-diagnosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.851391/full

Similar Items

Treatment of Advanced NSCLC with Unknown EGFR Gene Status __ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01)

Identification of Gefitinib Resistance-Related lncRNA-miRNA-mRNA Regulatory Networks and Corresponding Prognostic Signature in Patients with Lung Adenocarcinoma
by: Wang T, et al.
Published: (2022-09-01)

Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis
by: Dandan Ding, et al.
Published: (2024-05-01)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022-08-01)

Long non-coding RNA LINC01128 affects proliferation, migration, and invasion of glioma cells by regulating miR-27b-3p
by: Qi Zhang, et al.
Published: (2022-09-01)

Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review
by: Nikhil Samarth, et al.
Published: (2022-12-01)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
by: Tohru Ohmori, et al.
Published: (2021-01-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
by: Shiyu Li, et al.
Published: (2022-12-01)

Targeting HER3 to overcome EGFR TKI resistance in NSCLC
by: Qiuqiang Chen, et al.
Published: (2024-01-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01)

Detection of <i>EGFR</i> Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
by: Annamaria Siggillino, et al.
Published: (2020-12-01)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
by: Xin Li, et al.
Published: (2020-03-01)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
by: Yangchun Gu, et al.
Published: (2021-12-01)

LINC01128 - miR-16 interaction regulates the migration and invasion of human chorionic trophoblast cells
by: Xinyuan Zhao, et al.
Published: (2021-04-01)

LINC01128 expedites cervical cancer progression by regulating miR-383-5p/SFN axis
by: Yi Hu, et al.
Published: (2019-11-01)

Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma
by: Junyou Zhu, et al.
Published: (2020-09-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
by: Yu Wang, et al.
Published: (2023-09-01)

Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review
by: Ran CHEN, et al.
Published: (2022-08-01)

A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC
by: Yongxing Li, et al.
Published: (2019-06-01)

Research Progress of the Resistance Mechanism of Non-small Cell Lung Cancer  to EGFR-TKIs
by: Huihui LIU, et al.
Published: (2013-10-01)

Survival-Related lncRNA Landscape Analysis Identifies LINC01614 as an Oncogenic lncRNA in Gastric Cancer
by: Huijie Wu, et al.
Published: (2021-10-01)

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
by: Zhenzhen Pan, et al.
Published: (2022-03-01)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
by: Yuan Gao, et al.
Published: (2017-07-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
by: Wuwu Ding, et al.
Published: (2024-01-01)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020-07-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
by: Shunli Peng, et al.
Published: (2019-11-01)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
by: John Wen‐Cheng Chang, et al.
Published: (2023-02-01)

Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review
by: Puchun Er, et al.
Published: (2017-08-01)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
by: Fangqiu Fu, et al.
Published: (2021-04-01)

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
by: Qian Hua, et al.
Published: (2021-10-01)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
by: Yingying Pan, et al.
Published: (2019-04-01)

LncRNA PELATON, a Ferroptosis Suppressor and Prognositic Signature for GBM
by: Haijuan Fu, et al.
Published: (2022-04-01)

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs  in Lung Adenocarcinoma Patients with EGFR Gene Mutations
by: Xiang ZHU, et al.
Published: (2014-02-01)

Vinorelbine Alters lncRNA Expression in Association with EGFR Mutational Status and Potentiates Tumor Progression Depending on NSCLC Cell Lines’ Genetic Profile
by: Hasan Alsharoh, et al.
Published: (2023-12-01)